|
|
Article: Mount Sinai School of Medicine and Medisyn Technologies Announce Agreement to Discover Novel Therapeutics for Treating Alzheimer's Disease.
- Article from:
- Business Wire
- Article date:
- September 13, 2007
CopyrightCOPYRIGHT 2007 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
NEW YORK & MINNEAPOLIS -- Mount Sinai School of Medicine (MSSM) and Medisyn Technologies today announced a collaboration for the development of novel b-amyloid (Ab) lowering drugs as a treatment in Alzheimer's disease. Starting with MSSM's previous research data obtained from testing early-stage lead compounds, the collaboration utilizes Medisyn Technologies' molecular topology Forward Engineering[TM] platform to build a diverse pipeline of Alzheimer's disease drug candidates. The goal of the study is to complete in vivo efficacy validation of the novel drug candidates by the end of 2007.
It is estimated that 4.5 Americans currently suffer from Alzheimer's ...
Related newspaper, magazine, and journal articles:
|
|
Article: Eidogen-Sertanty Licenses Kinase Database to Medisyn ...
Business Wire;
September 7, 2005 ;
700+ words
... ... licensed their Kinase Knowledgebase(TM) to Medisyn Technologies, a Minnesota-based early-stage drug ... press-7-26-2005.htm. About Medisyn Technologies Medisyn Technologies, Inc. is an early stage, privately ...
|
|